Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219120 | 0.92 | CNR1 (0.37) | CNR1CNR2MCHR1LMNAHPGD | |
| SCHEMBL7106026 | 0.88 | NR1H4 (0.36) | CNR1MCHR1EPHX1EPHX2SCN5A | |
| SCHEMBL14254759 | 0.82 | ITGAL (0.36) | MCHR1EPHX1EPHX2SCN5A | |
| SCHEMBL14254855 | 0.81 | ITGAL (0.46) | CNR1TSHREPHX2 | |
| SCHEMBL4846595 | 0.79 | NR1H4 (0.44) | — | |
| SCHEMBL4847498 | 0.79 | ITGAL (0.39) | TSHR | |
| SCHEMBL4847326 | 0.79 | ITGAL (0.39) | — | |
| SCHEMBL4848864 | 0.78 | LMNA (0.39) | MCHR1LMNAHPGDTSHR | |
| SCHEMBL4848531 | 0.77 | AGTR1 (0.44) | — | |
| SCHEMBL4844859 | 0.76 | ITGAL (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | CNR1 3670/4885CNR2 2608/4885MCHR1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.